GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18

• Published in: Frontiers in immunology Vol. 13; p. 839783
• Main Authors: Glienke, Wolfgang, Dragon, Anna Christina, Zimmermann, Katharina, Martyniszyn-Eiben, Alexandra, Mertens, Mira, Abken, Hinrich, Rossig, Claudia, Altvater, Bianca, Aleksandrova, Krasimira, Arseniev, Lubomir, Kloth, Christina, Stamopoulou, Andriana, Moritz, Thomas, Lode, Holger N., Siebert, Nikolai, Blasczyk, Rainer, Goudeva, Lilia, Schambach, Axel, Köhl, Ulrike, Eiz-Vesper, Britta, Esser, Ruth
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 24.03.2022
• Subjects: 4th generation CAR; GD2-CAR; GMP; IL-18; Immunology; Prodigy; TRUCK
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.839783

Chimeric antigen receptor (CAR)-engineered T cells can be highly effective in the treatment of hematological malignancies, but mostly fail in the treatment of solid tumors. Thus, approaches using 4 th advanced CAR T cells secreting immunomodulatory cytokines upon CAR signaling, known as TRUCKs (“ T cells redirected for universal cytokine-mediated killing ”), are currently under investigation. Based on our previous development and validation of automated and closed processing for GMP-compliant manufacturing of CAR T cells, we here present the proof of feasibility for translation of this method to TRUCKs. We generated IL-18-secreting TRUCKs targeting the tumor antigen GD 2 using the CliniMACS Prodigy ® system using a recently described “all-in-one” lentiviral vector combining constitutive anti-GD 2 CAR expression and inducible IL-18. Starting with 0.84 x 10 8 and 0.91 x 10 8 T cells after enrichment of CD4 + and CD8 + we reached 68.3-fold and 71.4-fold T cell expansion rates, respectively, in two independent runs. Transduction efficiencies of 77.7% and 55.1% was obtained, and yields of 4.5 x 10 9 and 3.6 x 10 9 engineered T cells from the two donors, respectively, within 12 days. Preclinical characterization demonstrated antigen-specific GD 2 -CAR mediated activation after co-cultivation with GD 2 -expressing target cells. The functional capacities of the clinical-scale manufactured TRUCKs were similar to TRUCKs generated in laboratory-scale and were not impeded by cryopreservation. IL-18 TRUCKs were activated in an antigen-specific manner by co-cultivation with GD 2 -expressing target cells indicated by an increased expression of activation markers (e.g. CD25, CD69) on both CD4 + and CD8 + T cells and an enhanced release of pro-inflammatory cytokines and cytolytic mediators (e.g. IL-2, granzyme B, IFN-γ, perforin, TNF-α). Manufactured TRUCKs showed a specific cytotoxicity towards GD 2 -expressing target cells indicated by lactate dehydrogenase (LDH) release, a decrease of target cell numbers, microscopic detection of cytotoxic clusters and detachment of target cells in real-time impedance measurements (xCELLigence). Following antigen-specific CAR activation of TRUCKs, CAR-triggered release IL-18 was induced, and the cytokine was biologically active, as demonstrated in migration assays revealing specific attraction of monocytes and NK cells by supernatants of TRUCKs co-cultured with GD 2 -expressing target cells. In conclusion, GMP-compliant manufacturing of TRUCKs is feasible and delivers high quality T cell products.